Back to top
more

BeyondSpring (BYSI)

(Delayed Data from NSDQ)

$2.43 USD

2.43
97,152

+0.14 (6.11%)

Updated Apr 24, 2024 04:00 PM ET

After-Market: $2.42 -0.01 (-0.41%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (78 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Clene Inc. (CLNN) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Clene Inc. (CLNN) delivered earnings and revenue surprises of -4.76% and 46.15%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Humanigen Inc. (HGEN) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Humanigen Inc. (HGEN) delivered earnings and revenue surprises of -26.47% and 0.39%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Wave Life Sciences (WVE) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Wave Life Sciences (WVE) delivered earnings and revenue surprises of -10.71% and 88.46%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Codexis (CDXS) Surges 9.7%: Is This an Indication of Further Gains?

by Zacks Equity Research

Codexis (CDXS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

VistaGen Therapeutics, Inc. (VTGN) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

VistaGen Therapeutics, Inc. (VTGN) delivered earnings and revenue surprises of -33.33% and 88.18%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

HealthEquity (HQY) Q1 Earnings Miss Estimates

by Zacks Equity Research

HealthEquity (HQY) delivered earnings and revenue surprises of -3.57% and 1.46%, respectively, for the quarter ended April 2022. Do the numbers hold clues to what lies ahead for the stock?

Affimed N.V. (AFMD) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Affimed N.V. (AFMD) delivered earnings and revenue surprises of 11.11% and 9.57%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Palatin Technologies, Inc. (PTN) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Palatin Technologies, Inc. (PTN) delivered earnings and revenue surprises of 0% and 62.76%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

BeyondSpring Inc. (BYSI) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

BeyondSpring Inc. (BYSI) delivered earnings and revenue surprises of 18.97% and 0.88%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

BeyondSpring Inc. (BYSI) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

BeyondSpring Inc. (BYSI) delivered earnings and revenue surprises of 0.00% and -97.56%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Biotech Stock Roundup: REGN Q2 Earnings Beat, BLUE, BYSI's Updates & More

by Zacks Equity Research

The biotech sector was in focus last week on earnings results from Regeneron (REGN) and regulatory update from bluebird (BLUE) among others.

Share Gain in Core Markets to Aid Medtronic (MDT) Q4 Earnings

by Zacks Equity Research

Growing momentum in capital equipment purchases might have aided Medtronic (MDT) Q4 earnings.

4 Biotech Stocks Set to Outpace Q1 Earnings Estimates

by Zacks Equity Research

Let us take a look at some drug/biotech stocks that are poised to beat on first-quarter earnings.

GT Biopharma (GTBP) to Report Q1 Earnings: What to Expect?

by Zacks Equity Research

GT Biopharma (GTBP) is expected to provide updates on its pipeline development when it reports first-quarter 2021 result.

BeyondSpring (BYSI) Looks Good: Stock Adds 5.1% in Session

by Zacks Equity Research

BeyondSpring (BYSI) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

BeyondSpring (BYSI) Catches Eye: Stock Jumps 10.9%

by Zacks Equity Research

BeyondSpring (BYSI) saw a big move last session, as its shares jumped nearly 11% on the day, amid huge volumes.

Can The Uptrend Continue for BeyondSpring (BYSI)?

by Zacks Equity Research

Investors certainly have to be happy with BeyondSpring Inc. (BYSI) and its short term performance.

BeyondSpring Sees Hammer Chart Pattern: Time to Buy?

by Zacks Equity Research

BeyondSpring has been struggling lately, but the selling pressure may be coming to an end soon.

    BeyondSpring Inc. (BYSI) Sees Hammer Chart Pattern: Time to Buy?

    by Zacks Equity Research

    BeyondSpring Inc. (BYSI) Sees Hammer Chart Pattern: Time to Buy?

      Why BeyondSpring (BYSI) Could Be a Potential Winner

      by Zacks Equity Research

      Although overlooked by the investors, BeyondSpring (BYSI) looks well-positioned for a solid gain, supported by a favorable Zacks rank and positive estimate revisions.